Drug
Encorafenib clinical trials
Also written LGX818, Braftovi and ONO-7702.
- studies test it
- 58
- open now
- 14
- in phase 3
- 7
- first study started
- 2011
Keep track of what changes. Save the encorafenib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
58 studies that test it; most in 2019 (8)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 5 |
| 2018 | 4 |
| 2019 | 8 |
| 2020 | 7 |
| 2021 | 7 |
| 2022 | 5 |
| 2023 | 4 |
| 2024 | 7 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 16
- Phase 2
- 38
- Phase 3
- 7
- Phase 4
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 23
Who runs them
Industry 24 · Other 34
Pfizer (15) · M.D. Anderson Cancer Center (5) · Pierre Fabre Medicament (4) · National Cancer Institute (NCI) (2) · Memorial Sloan Kettering Cancer Center (2) · Array BioPharma (2) · Peter MacCallum Cancer Centre, Australia (2) · Gruppo Oncologico del Nord-Ovest (1)
Often tested with
Tested in the same studies.
Binimetinib (35) · Cetuximab (15) · Pembrolizumab (6) · Nivolumab (5) · Dabrafenib (3) · Trametinib (3) · Ipilimumab (3) · Palbociclib (3)
Studies
Open first, then newest update. How each study uses encorafenib is read from its arms, and is right about nine times in ten.
Testing it · 58
- The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical TrialsRecruitingPhase 4PfizerNCT05203172Written as Encorafenib
- ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal CancerRecruitingEarly Phase 1M.D. Anderson Cancer CenterNCT07318389Written as Encorafenib
- Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal CancerRecruitingPhase 1National Cancer Institute (NCI)NCT06102902Written as Encorafenib
- A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain MetastasesRecruitingPhase 2SWOG Cancer Research NetworkNCT04511013Written as Encorafenib
- Open-label Phase 1b Study of Ulixertinib and Cetuximab or Ulixertinib in Combination With Cetuximab and Encorafenib in Patients With Unresectable or Metastatic Colorectal Cancer Who Have Previously Received EGFR or BRAF-directed TherapyRecruitingPhase 1M.D. Anderson Cancer CenterNCT05985954Written as Encorafenib
- Personalized Medicine for Advanced Biliary Cancer PatientsRecruitingPhase 3UNICANCERNCT05615818Written as Encorafenib
- Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System MetastasesRecruitingPhase 2M.D. Anderson Cancer CenterNCT05026983Written as Encorafenib
- Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous MelanomaRecruitingPhase 1/2University of UtahNCT06194929Written as Encorafenib
- Encorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum CancerRecruitingPhase 2Federation Francophone de Cancerologie DigestiveNCT05706779Written as Encorafenib Oral Capsule + Cetuximab
- Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.RecruitingPhase 2Fondazione Policlinico Universitario Agostino Gemelli IRCCSNCT06640166Written as encorafenib + cetuximab + FOLFIRI
- Combination Therapy for BRAF-V600E Metastatic CRCmRecruitingPhase 2Vall d'Hebron Institute of OncologyNCT06411600Written as Encorafenib
- Encorafenib, Binimetinib and Palbociclib in BRAF-mutant Metastatic Melanoma CELEBRATERecruitingPhase 1/2Peter MacCallum Cancer Centre, AustraliaNCT04720768Written as Encorafenib
- Melanoma Metastasized to the Brain and SteroidsRecruitingPhase 2Inge Marie SvaneNCT03563729Written as Encorafenib
- Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal CancerRecruitingPhase 2Oslo University HospitalNCT05725200Written as Encorafenib
- Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node InvolvementTerminatedPhase 2ECOG-ACRIN Cancer Research GroupNCT04221438Written as Encorafenib
- Phase II Study of ctDNA-guided Encorafenib Plus Cetuximab Retreatment in Patients BRAF V600E Mutated mCRCActive, not recruitingPhase 2Gruppo Oncologico del Nord-OvestNCT06578559Written as Encorafenib
- A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic MelanomaActive, not recruitingPhase 3PfizerNCT04657991Written as Encorafenib
- ENCOrafenib With Binimetinib in bRAF NSCLCActive, not recruitingPhase 2Intergroupe Francophone de Cancerologie ThoraciqueNCT04526782Written as Encorafenib 75 MG
- A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal CancerActive, not recruitingPhase 2PfizerNCT05217446Written as Encorafenib
- Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal CancerCompletedPhase 2Pierre Fabre MedicamentNCT03693170Written as encorafenib
See all 58 studies that test encorafenib →
Given in every arm · 13 — encorafenib is usual care beside what is tested
- Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic MelanomaRecruitingPhase 1Rina PlattnerNCT04903119Written as Encorafenib
- Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF MutationActive, not recruitingPhase 2National Cancer Institute (NCI)NCT05308446Written as Encorafenib
- Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain MetastasisActive, not recruitingPhase 2UNICANCERNCT04074096Written as Encorafenib Oral Capsule
- PF-07284892 in Participants With Advanced Solid TumorsTerminatedPhase 1PfizerNCT04800822Written as encorafenib
- A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer.CompletedPhase 2Pierre Fabre MedicamentNCT05004350Written as Encorafenib
- Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid CancerActive, not recruitingPhase 2Providence Health & ServicesNCT04061980Written as Encorafenib
- A Study of ERAS-007 in Patients With Advanced Gastrointestinal MalignanciesCompletedPhase 1/2Erasca, Inc.NCT05039177Written as Encorafenib
- Overcoming Primary Resistance to Immunotherapy in Metastatic MelanomaCompletedPhase 2Dr. Ronnie ShapiraNCT05304546Written as Encorafenib
- Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose IpilimumaTerminatedPhase 1/2Jason J. Luke, MDNCT04655157Written as encorafenib
- A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advanced Solid TumorsCompletedPhase 1/2PfizerNCT01543698Written as LGX818
- A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic CancerCompletedPhase 1Eli Lilly and CompanyNCT02857270Written as Encorafenib
- Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal CancerCompletedPhase 2PfizerNCT01719380Written as LGX818
- Safety and Efficacy of LEE011 and LGX818 in Patients With BRAF Mutant Melanoma.TerminatedPhase 1/2Array BioPharmaNCT01777776Written as LGX818
Codes
What other systems call encorafenib · ClinicalTrials.gg INT000307
- MeSH (NLM) C000601108encorafenibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8L7891MRB6ENCORAFENIBConfirmed FDA, NLM, Wikidata
- RxNorm 2049106Confirmed FDA, Wikidata
- Wikidata Q15409405encorafenibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C98283EncorafenibOne source FDA
- DrugBank DB11718One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000601108 | encorafenib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8L7891MRB6 | ENCORAFENIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2049106 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15409405 | encorafenib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C98283 | Encorafenib | One source FDA |
| DrugBank | DB11718 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.